|
|
|
|
TopoTarget Partner, Spectrum Pharmaceuticals, to host Conference Call Thursday 4 February 2010 at 19:00 CET (1
- TopoTarget A/S (NASDAQ-OMX: TOPO.CO) and Spectrum Pharmaceuticals Inc.(NASDAQ: SPPI) announced on 2 February 2010 (Announcement No 02-10) an agreement to co-develop and commercialize belinostat, TopoTarget's lead anticancer drug for cancer in North America...
|
|
|
TopoTarget Partner, Spectrum Pharmaceuticals, to host Conference Call Thursday 4 February 2010 at 19:00 CET (1
TopoTarget A/S Symbion Fruebjergvej 3 DK 2100 Copenhagen Denmark Tel: +45 39 17 83 92 Fax: +45 39 17 94 92 CVR-nr: 25695771 www.topotarget.com Copenhagen, Denmark - 4 February, 2010 - TopoTarget A/S (NASDAQ-OMX: TOPO.CO) and Spectrum Pharmaceuticals Inc....
|
|
|
Bortezomib (Velcade) Starting Dose Adjustments for Patients With Hepatic Impairment
Medwatch (01/26/2010) The FDA has issued a notification for healthcare professionals regarding revisions to the Prescribing Information for bortezomib (Velcade).These changes pertain to patients with hepatic impairment at the start of bortezomib...
|
|
|
Research and Markets: Drive the Roadmap for Success in Oncology as Global Oncology Market is Projected to Outg
Research and Markets (http://www.researchandmarkets.com/research/d7939f/roadmap_for_succes) has announced the addition of the 'Roadmap for Success in Oncology' report to their offering.The worldwide oncology market is projected to outgrow the rest of the...
|
|
|
Velcade (bortezomib): Starting Dose Adjustments-Patients with moderate/severe Hepatic Impairment Should be Tre
Audience: Hematology, Oncology healthcare professionals ROCKVILLE, Md., Jan.26, 2010--Takeda Oncology and FDA notified healthcare professionals about revisions to the Prescribing Information for Velcade, section 2.5, pertaining to patients with hepatic...
|
|
|
Revised Velcade Dosing for Patients with Hepatic Impairment
Takeda Oncology has revised the prescribing information for Velcade (bortezomib) to include new safety information for patients with moderate to severe hepatic impairment.These patients should be started on Velcade at a reduced dose compared to...
|
|
|
Millennium Pharma issues cancer-drug warning
Boston Business Journal - by Send this story to a friend address of friend (insert comma between multiple addresses): Your email address: Add a brief note: Enter words from the security image above: reCAPTCHA Related has sent a letter to health care...
|
|
|
Velcade (bortezomib): Starting Dose Adjustments-Patients with moderate/severe Hepatic Impairment Should be Tre
Audience: Hematology, Oncology healthcare professionals ROCKVILLE, Md., Jan.26, 2010--Takeda Oncology and FDA notified healthcare professionals about revisions to the Prescribing Information for Velcade, section 2.5, pertaining to patients with hepatic...
|
|
|
Health Canada approves first post-surgical treatment for patients with gastrointestinal stromal tumours
Study examines relationship between parental vaccine refusal and risk of varicella infection in childrenChildren of parents who refuse vaccines are nine times more likely to get chickenpox compared to ful...Eli Lilly and Kowa Pharmaceuticals America to co...
|
|
|
Millennium issues cancer-drug warning
has sent a letter to health care professionals advising them to lower the dosage of the companys cancer drug in certain patients.The drug, Velcade, is approved for the treatment of multiple myeloma and also is approved as a second-line treatment for...
|
|
|
Millennium Pharma issues cancer-drug warning
has sent a letter to health care professionals advising them to lower the dosage of the companys cancer drug in certain patients.The drug, Velcade, is approved for the treatment of multiple myeloma and also is approved as a second-line treatment for...
|
|
|
J&J Beats, Guidance Disappoints
Johnson & Johnson (JNJ) reported fourth quarter earnings of 79 cents, which was impacted by a restructuring charge.However, excluding extraordinary items, the company's earnings per share came in at $1.02, surpassing the Zacks Consensus Estimate of...
|
|
|
Velcade Prescribing Information Changed
Takeda Oncology and the U.S.Velcade Prescribing Information Changed.
|
|
|
Millennium Pharma issues cancer-drug warning
Millennium Pharmaceuticals Inc.has sent a letter to health care professionals advising them to lower the dosage of the companys cancer drug in certain patients. The drug, Velcade, is approved for the treatment of multiple myeloma and also is approved...
|
|
|
Millennium Pharma issues cancer-drug warning
has sent a letter to health care professionals advising them to lower the dosage of the companys cancer drug in certain patients.The drug, Velcade, is approved for the treatment of multiple myeloma and also is approved as a second-line treatment for...
|
|
|
Millennium Pharma issues cancer-drug warning
Millennium Pharmaceuticals Inc.has sent a letter to health care professionals advising them to lower the dosage of the companys cancer drug in certain patients. The drug, Velcade, is approved for the treatment of multiple myeloma and also is approved...
|
|
|
FDA Updates Myeloma Drug Label for New Risks
WASHINGTON -- The FDA has revised dosage and safety information for bortezomib (Velcade), the myeloma and mantle cell lymphoma drug, to reflect an increased toxicity risk.The new labeling includes a warning for patients with moderate-to-severe hepatic...
|
|
|
J&J Q4: Beats Estimates, Guidance Disappoints
Johnson & Johnson (JNJ) reported fourth quarter earnings of 79 cents, which was impacted by a restructuring charge.However, excluding extraordinary items, the companys earnings per share came in at $1.02, surpassing the Zacks Consensus Estimate of 97...
|
|
|
Millennium, In a New Role, Flexes Global Muscle to Cut Deal With Seattle Genetics
Life Sciences , Antibodies , R&D Ryan McBride wrote: Millennium is playing the role of global development and marketing partner to Seattle Genetics, something that would have been tricky for Cambridge, MA-based Millennium to nail before it became the cancer...
|
|
|
University of Pittsburgh Schools of the Health Sciences: Drug shows promise as new treatment for gut tumor
Drug shows promise as new treatment for gut tumor A drug that is already an approved therapy for some cancers also might be an effective secondary treatment for a rare tumor of the gastrointestinal tract, according to a team led by researchers from the...
|
|
|
Survival data on Bortezomib label
Data showing a 35 per cent improvement in long-term overall survival when patients with multiple myeloma are treated with bortezomib as initial therapy have been added to the prescribing information for the drug, according to the manufacturer.Millennium: The...
|
|
|
Bortezomib Inhibits Hepatitis B Virus Replication in Transgenic Mice
Pharmacological modulation of cellular proteins as a means to block virus replication has been proposed as an alternative antiviral strategy that may be less susceptible than others to the development of viral drug resistance.Recent evidence indicates that...
|
|
|
Majestic Research Finds Hematologists/Oncologists Expect To Change Multiple Myeloma Treatment Practices Due To
In a study published by Majestic Research's Market Research Group (formerly Rood Research), it was found that many hematologists and oncologists who attended the American Society of Hematology (ASH) 2009 Annual Meeting expect to change their multiple myeloma...
|
|
|
Majestic Research Finds Hematologists/Oncologists Expect to Change Multiple Myeloma Treatment Practices Due to
- In a study published by Majestic Research's (formerly Rood Research), it was found that many hematologists and oncologists who attended the American Society of Hematology (ASH) 2009 Annual Meeting expect to change their multiple myeloma treatment practices,...
|
|
|
Majestic Research Finds Hematologists/Oncologists Expect to Change Multiple Myeloma Treatment Practices Due to ASH 2009 Data
NEW YORK--(BUSINESS WIRE)--In a study published by Majestic Research?s (formerly Rood Research), it was found that many hematologists and oncologists who attended the American Society of Hematology (ASH) 2009 Annual Meeting expect to change their multiple...
|
